First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Status:
Completed
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test an investigational combination of drugs for bile duct or
gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in
combination to treat bile duct and gallbladder cancers. The investigators are looking to
improve treatment results. They will attempt to do so by adding the drug MEK162 to the
treatment plan. MEK162 acts by blocking a protein called MEK 1/2 which helps cancer cells
grow and divide. This study will help answer the question of whether MEK162 is a helpful drug
in patients with bile duct or gallbladder cancers when given with gemcitabine and cisplatin.